Amarin Entered into an Exclusive Commercialization Agreement with Neopharm for Vazkepa (Icosapent Ethyl) in Israel
Shots:
- The companies collaborated to commercialize Vazkepa (icosapent ethyl) in the State of Israel, Gaza, West Bank & territories of the Palestinian Authority
- The agreement follows recent regulatory approval in Israel of Vazkepa to reduce the risk of CV events in adult statin-treated patients at high CV risk with elevated triglycerides and other high-risk characteristics as studied in (REDUCE-IT)
- Neopharm will be the sole distributor of Vazkepa in Israel & gets the right to hold under its name the regulatory approvals and regulatory filings as the marketing authorization holder for Vazkepa in this territory while Amarin will supply the finished product to Neopharm at a transfer price paid to Amarin
Ref: GlobeNewswire | Image: Amarin
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
